Literature DB >> 21659857

Symmetrical drug-related intertriginous and flexural exanthema.

Sze-Chin Tan1, Justina W-L Tan.   

Abstract

PURPOSE OF REVIEW: Symmetrical drug-related intertriginous and flexural exanthema (SDRIFE), previously termed drug-related baboon syndrome, is a benign and self-limiting type IV hypersensitivity reaction characterized by symmetrical erythema involving the gluteal and intertriginous areas in the absence of systemic involvement. It may also occur in the absence of previous drug exposure. RECENT
FINDINGS: Antibiotics, in particular beta-lactams, comprise the majority of causes of SDRIFE. Other drugs which have been implicated include antihypertensives, radiocontrast media, chemotherapeutic agents, and biologics. Histology of lesional skin is variable with predominance of superficial perivascular inflammatory cell infiltrates. Outcomes of allergy tests are variable with positive delayed intradermal tests reported for penicillin V, allopurinol; positive patch tests for erythromycin, mitomycin, nystatin, pseudoephdrine; positive lymphocyte transformation tests for erythromycin; and positive drug provocation tests for clindamycin, cimetidine, corticosteroids, terbinafine, and valacyclovir.
SUMMARY: Diagnosis of SDRIFE is dependent upon recognition of the clinical morphology and distribution of the rash, and its temporal relationship to the use of the suspected drug. Outcomes of in-vivo and in-vitro tests have been inconsistent, and thus may not be useful in the identification of the putative drug.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21659857     DOI: 10.1097/ACI.0b013e3283489d5f

Source DB:  PubMed          Journal:  Curr Opin Allergy Clin Immunol        ISSN: 1473-6322


  18 in total

1.  Symmetrical drug-related intertriginous and flexural exanthema (Baboon syndrome) associated with infliximab.

Authors:  Isil Bulur; Havva Ozge Keseroglu; Zeynep Nurhan Saracoglu; Müzeyyen Gönül
Journal:  J Dermatol Case Rep       Date:  2015-03-31

2.  Symmetrical drug-related intertriginous and flexural exanthema due to clindamycin.

Authors:  Virginia Cabrera Hernandez; Monica Gonzalez Afonso; Ariel Callero Viera; Lidon Martin-Fernandez Martin
Journal:  BMJ Case Rep       Date:  2019-08-02

3.  An unusual case of worsening cellulitis: baboon syndrome or SDRIFE.

Authors:  Shane Fischbach; Natalie Hall; Sandeep Bains; Vijairam Selvaraj
Journal:  BMJ Case Rep       Date:  2018-03-28

4.  Co-occurrence of Symmetrical Drug-Related Intertriginous and Flexural Exanthema (SDRIFE) and Pigmented Fixed Drug Eruption (FDE) in a Single Patient Due to Doxycycline: A Case Report.

Authors:  Kananbala Sahu; Chandra S Sirka; Swetalina Pradhan; Arpita N Rout
Journal:  Indian Dermatol Online J       Date:  2020-01-13

5.  Symmetrical Drug-Related Intertriginous and Flexural Exanthema: Two Cases and Brief Literature Review.

Authors:  Joon Seok; Jae Min Kim; Kui Young Park; Seong Jun Seo
Journal:  Ann Dermatol       Date:  2018-08-28       Impact factor: 1.444

6.  First Report of Symmetrical Drug-related Intertriginous and Flexural Exanthema (SDRIFE or Baboon Syndrome) After Erenumab Application for Migraine Prevention.

Authors:  Carl H Göbel; Axel Heinze; Sarah Karstedt; Anna Cirkel; Thomas F Münte; Hartmut Göbel
Journal:  Pain Ther       Date:  2022-07-31

Review 7.  Baboon syndrome: an unusual complication arising from antibiotic treatment of tonsillitis and review of the literature.

Authors:  James Peter Blackmur; Simon Lammy; David E C Baring
Journal:  BMJ Case Rep       Date:  2013-11-28

Review 8.  Systemic Contact Dermatitis.

Authors:  Marcella Aquino; Greg Rosner
Journal:  Clin Rev Allergy Immunol       Date:  2019-02       Impact factor: 8.667

9.  [Delayed-type cutaneous drug reactions. Pathogenesis, clinical features and histology].

Authors:  M Ziemer
Journal:  Hautarzt       Date:  2014-05       Impact factor: 0.751

Review 10.  Contact Dermatitis: Classifications and Management.

Authors:  Yan Li; Linfeng Li
Journal:  Clin Rev Allergy Immunol       Date:  2021-07-15       Impact factor: 8.667

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.